Biophysical and mechanobiological considerations for T-cell-based immunotherapy
Trends in Pharmacological Sciences · 2023-06 · 44 (6) · 366-378
DOI: 10.1016/j.tips.2023.03.007 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Pharmacological Sciences, 2023-06. Verfasst von Chuzhi Zhuang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Yale University, New Haven, CT 06511, USA. Hauptthemen laut MEDLINE: T-Lymphocytes, Neoplasms. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, Yale University, New Haven, CT 06511, USA.
- Department of Biomedical Engineering, Yale University, New Haven, CT 06511, USA. Electronic address: michael.mak@yale.edu.
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- National Institutes of Health
- National Cancer Institute
- National Institute of General Medical Sciences
Zitieren
APA
Zhuang, C., Gould, J. E., Enninful, A., Shao, S., & Mak, M. (2023). Biophysical and mechanobiological considerations for T-cell-based immunotherapy. Trends in Pharmacological Sciences, 44(6), 366-378. https://doi.org/10.1016/j.tips.2023.03.007
Vancouver
Zhuang C, Gould JE, Enninful A, Shao S, Mak M. Biophysical and mechanobiological considerations for T-cell-based immunotherapy. Trends in Pharmacological Sciences. 2023;44(6):366-378. doi:10.1016/j.tips.2023.03.007
BibTeX
@article{Zhuang2023,
author = {Zhuang, Chuzhi and Gould, Jared E and Enninful, Archibald and Shao, Stephanie and Mak, Michael},
title = {Biophysical and mechanobiological considerations for T-cell-based immunotherapy},
journal = {Trends in Pharmacological Sciences},
year = {2023},
volume = {44},
number = {6},
pages = {366--378},
doi = {10.1016/j.tips.2023.03.007}
}
EUVIMED